Business Wire

CSC Finds Majority of World’s Largest Companies Susceptible to Phishing and Brand Abuse Due to Improper Domain Security

28.9.2021 16:00:00 EEST | Business Wire | Press release

Share

CSC, a world leader in business, legal, tax, and domain security, today released its annual Domain Security Report: Forbes Global 2000 Companies , which found that despite the shift to modernize business environments and operations among the Global 2000 companies, web domains remain dangerously under protected.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928005027/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Key findings from the 2021 Domain Security Report (Graphic: Business Wire)

CSC’s research also shows that most Global 2000 companies continue to lag in the adoption of domain security measures. Most notably, 81% of companies are not using registry locks. Other concerning findings illustrate that domain security remains an afterthought for many brands:

  • 70% of homoglyph (fuzzy match) domains—a tactic commonly used in phishing and brand abuse—are owned by third parties
  • 57% of the Global 2000 are relying on off-the-shelf consumer-grade registrars who offer limited domain security mechanisms to protect against domain and DNS hijacking

“Basic domain security measures continue to get overlooked because they’re still not considered an essential component to a company’s broader phishing, business email compromise, or ransomware mitigation approach,” said Mark Calandra, president of CSC Digital Brand Services. “A focus on securing legitimate domains while monitoring for malicious domains in parallel needs to be a bigger priority for companies to stay protected and thwart cyber risk. Otherwise, companies are exposing themselves to significant threats to their cyber security posture, data protection, intellectual property, supply chains, consumer safety, revenue, and reputation.”

CSC’s additional findings leave little doubt that bad actors are applying tactics to hide their tracks and accelerate their attempts to execute their attacks. The research found that among the 70% of third-party domains deemed suspicious:

  • 77% used domain privacy services or also had WHOIS details redacted
  • 43% are configured with MX email records, giving them the ability to send phishing emails
  • 56% were pointing to advertising, pay-per-click content, or being used for domain parking
  • 38% had inactive web content
  • 6% were pointing to brand impersonation and malicious content including phishing and potential malware delivery

The rise of cyber crime and digital fraud, along with a steady increase in domain registrations over the last 18 months, necessitates more industry oversight. At the same time, it’s imperative that companies get proactive with their domain security moving forward. Including security measures can help mitigate phishing—a common starting point in most ransomware attacks. Companies need to take a more aggressive cyber security approach to disrupt criminal activities taking place across their domain ecosystem.

Download the report now at cscdbs.com/securityreport .

To learn more about CSC’s approach to domain security, visit cscdbs.com.

About CSC

CSC is the trusted provider of choice for the Forbes Global 2000 and the 100 Best Global Brands® for enterprise domain names, domain name system, and digital certificate management, as well as digital brand, fraud, and phishing protection. We secure companies against cyber threats to their online assets using our proprietary security solutions, helping them avoid devastating revenue loss, brand reputation damage, or significant financial penalties. We also provide a combination of online brand monitoring and enforcement, taking a holistic approach to digital asset protection. Learn more about our domain management, security, brand protection, and fraud protection services at cscdbs.com.

Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Steve Bosk
W2 Communications
215-378-1056
CSC@w2comm.com
CSC Newsroom

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release

Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye